UK fines drug firms for hiking cost of epilepsy drug 2,600%

Drug firms Pfizer and Flynn Pharma have been fined nearly £90m (€106m) for "excessive and unfair" pricing to the NHS after hiking the cost of an anti-epilepsy drug by up to 2,600% overnight.

The UK's Competition and Markets Authority (CMA) said drug maker Pfizer and distributor Flynn Pharma broke competition law when they increased the cost of a medicine used by around 48,000 patients in the UK.